GlassScriptPhysician profile
Daniel F Collins
NPI 1104874320
$5,083.17
in general payments reported to CMS, 2019-2025
35 companies · $1,563 in 2025
The $1,563 reported for 2025 was more than what 93% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $856 · 2020: $11.68 · 2021: $241 · 2022: $541 · 2023: $816 · 2024: $1,056 · 2025: $1,563.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,434.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,434.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $711.32 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Indivior INC. | $657.83 | 2019-2025 | Sublocade |
| Abbvie INC. | $533.05 | 2022-2025 | Ubrelvy |
| Astrazeneca Pharmaceuticals LP | $510.76 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Pfizer INC. | $388.27 | 2019-2025 | |
| Inspire Medical Systems, INC. | $258.89 | 2024-2025 | Inspire |
| Novo Nordisk INC | $214.28 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| Vanda Pharmaceuticals INC. | $153.95 | 2022-2023 | Hetlioz |
| Amarin Pharma, INC. | $148.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $124.40 | 2019 | |
| Exact Sciences Corporation | $113.85 | 2023-2025 | Cologuard Collection Kit |
| Amgen INC. | $102.67 | 2023-2025 | Otezla, Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $98.47 | 2019 | |
| Braeburn INC. | $89.86 | 2024-2025 | Brixadi |
| Lilly USA, LLC | $87.67 | 2022-2023 | Mounjaro, Trulicity |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $84.41 | 2024-2025 | Capvaxive, Gardasil 9, Gardasil |
| Mdd US Operations, LLC | $78.17 | 2019 | |
| Paratek Pharmaceuticals, INC. | $60.49 | 2024-2025 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $58.19 | 2024-2025 | Rexulti |
| Actelion Pharmaceuticals US, INC. | $58.12 | 2024-2025 | Uptravi, Opsumit |
| Lundbeck LLC | $55.40 | 2025 | Rexulti |
| Antares Pharma, INC. | $51.91 | 2021-2025 | Xyosted |
| Edwards Lifesciences Corporation | $45.63 | 2025 | |
| Abbott Laboratories | $45.30 | 2025 | Freestyle Libre 3 |
| Verona Pharma, INC. | $42.87 | 2025 | Ohtuvayre |
| Boehringer Ingelheim Pharmaceuticals, INC. | $42.02 | 2019-2025 | Jascayd |
| Mylan Specialty L.P. | $41.45 | 2023 | Yupelri |
| Genentech USA, INC. | $40.89 | 2019 | |
| Theratechnologies INC. | $38.87 | 2024 | Egrifta, Trogarzo |
| Dexcom, INC. | $33.01 | 2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $31.26 | 2019 | |
| Axsome Therapeutics, INC. | $29.31 | 2025 | Auvelity |
| Collegium Pharmaceutical, INC. | $21.55 | 2019 | |
| Myriad Women'S Health, INC. | $15.98 | 2023 | Myrisk |
| Orexo US, INC. | $14.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Collins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.